Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)

Katharina Thom; Anthonie WA Lensing; Ildar Nurmeev; Fanny Bajolle; Damien Bonnet; Gili Kenet; M Patricia Massicotte; Zeynep Karakas; Joseph S Palumbo; Paola Saracco; Pascal Amedro; Juan Chain; Anthony K Chan; Takanari Ikeyama; Joyce CM Lam; Cynthia Gauger; Akos Ferenc Pap; Madhurima Majumder; Dagmar Kubitza; William T Smith; Scott D Berkowitz; Martin H Prins; Paul Monagle; Guy Young; Christoph Male

Journal article

Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)

Katharina Thom, Anthonie WA Lensing, Ildar Nurmeev, Fanny Bajolle, Damien Bonnet, Gili Kenet, M Patricia Massicotte, Zeynep Karakas, Joseph S Palumbo, Paola Saracco, Pascal Amedro, Juan Chain, Anthony K Chan, Takanari Ikeyama, Joyce CM Lam, Cynthia Gauger, Akos Ferenc Pap, Madhurima Majumder, Dagmar Kubitza, William T Smith Show all

Blood Advances | AMER SOC HEMATOLOGY | Published : 2020

DOI: 10.1182/bloodadvances.2020002637

Abstract

Anticoagulant treatment of pediatric central venous catheter-related venous thromboembolism (CVC-VTE) has not been specifically evaluated. In EINSTEIN-Jr, 500 children with any VTE received rivaroxaban or standard anticoagulants. A predefined analysis of the CVC-VTE cohort was performed. Children with CVC-VTE (age, birth to 17 years) were administered rivaroxaban or standard anticoagulants during the 1-month (children <2 years) or 3-month (all other children) study period. Predefined outcomes were recurrent VTE, change in thrombotic burden on repeat imaging, and bleeding. Predictors for continuation of anticoagulant therapy beyond the study period were evaluated. One hundred twenty-six child..

View full abstract